Don't let it get away!
Keep track of the stocks that matter to you.
Help yourself with the Fool's FREE and easy new watchlist service today.
Opko Health (NYSE: OPK ) has completed the acquisition of the privately held pharmaceutical company Cytochroma. This move adds two key products to Opko's portfolio, Replidea (CTAP101) and and Alpharen (Fermagate). The former is a vitamin D prohormone, and the latter is a non-absorbed phostphate binder. Both are used in the treatment of secondary hyperparathyroidism, a glandular condition, and are in phase 3 of their development.
The acquisition was first reported in January. Terms of the deal were not disclosed. Opko Health has been on something of a buyout streak lately; in February it announced it had completed the purchase of Brazilian company Silicon Comercio, Importacao E Exportacao de Produtos Farmaceuticos e Cosmeticos.